Navigation Links
Targeted agent shows promise in biliary cancer study
Date:4/20/2009

COLUMBUS, Ohio An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.

The agent, known as AZD6244 (ARRY-142886), blocks certain enzymes that cancer cells need to proliferate and survive.

About 100,000 patients are diagnosed with biliary cancer worldwide every year, representing 15-20 percent of all liver cancer cases. Most patients present at later stages of the disease, which has a universally poor outcome.

The findings of the 28-patient, phase II study will be reported April 20 at the annual meeting of the American Association for Cancer Research in Denver, Colorado.

"This is a malignancy for which there is no standard of care," says the study's principal investigator Dr. Tanios Bekaii-Saab, assistant professor of medicine and pharmacology, and a medical oncologist who specializes in gastrointestinal cancers at Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"And while it is a small study, it provides a strong rational for developing this agent further in larger trials either alone or in combination with other drugs, with the hope that we can establish a new standard of care for biliary cancers in the near future."

Bekaii-Saab noted that the average progression-free survival achieved by patients in the study was one of the highest reported in the literature for this malignancy with many patients gaining weight in a disease that is typically associated with significant weight loss. The drug, which is administered orally, seems to be well tolerated with mild toxicities.

The agent belongs to a class of drugs called protein kinase inhibitors. This particular drug targets a protein kinase called MEK 1/2, which is part of a chemical pathway that is often damaged in many biliary cancer cases, Bekaii-Saab says.

In addition to Ohio State, study sites included the University of North Carolina, Vanderbilt University and Emory University.

The patients, with an average age of 56 years, had advanced (metastatic) biliary cancer.

By the trial's end, one patient had a complete response to the treatment (the tumor shrank until it was undetectable), two patients had partial tumor shrinkage and 17 patients showed no further growth in tumor size; that is, they had stable disease which often was durable.

A preliminary analysis of the study shows that patients experienced no cancer progression for 5.4 months on average, a time almost double what would typically be expected with therapy in biliary cancer. This is despite the fact that 40 percent of patients had one prior therapy before receiving AZD6244. A more final analysis of the study is underway.

Patients who lacked a target protein called pERK did not seem to respond to the drug, suggesting that the drug may not work if the protein is missing in the cancer cells. "This is an important finding, as it suggests that we may be able to identify patients who may not respond to the drug in the future," he adds.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Targeted Treatments Show Mettle Against Advanced Cancers
2. UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases
3. Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign
4. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
5. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
6. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
7. Targeted nanospheres find, penetrate, then fuel burning of melanoma
8. Health Integrated Achieves NCQA Full Accreditation for Its Synergy Targeted Population Management(TM) Program
9. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
10. Anthem Blue Cross and Blue Shield Introduces SmartSense, Price-Conscious Plans Targeted at the Uninsured
11. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: